SecBot SecBot
8-K ·Filed May 11, 2026

RDNT

RadNet, Inc.
MIXED
Impact 6/10
Horizondays Processed6mo ago SEC0001683168-26-003624
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The revenue beat and guidance raise are positive, but the massive EPS miss and continued net losses create a conflicting signal. The stock may initially react negatively to the EPS miss, but the raised guidance and strong procedural volume growth could provide support. Watch for analyst reactions and the conference call for color on EPS trajectory and weather impact normalization.

DirectionMixed
Confidencehigh
Horizondays

Price Chart

Loading chart...

Executive Summary

RadNet reported record Q1 2026 revenue of $575.6M (+22.1% YoY) and raised full-year Imaging Center guidance for revenue, Adjusted EBITDA, and Free Cash Flow. However, the company posted a GAAP net loss of $33.5M and an adjusted diluted loss per share of $(0.28), significantly missing the consensus estimate of $0.21 EPS. The strong top-line growth and guidance raise are offset by the large EPS miss and continued net losses, creating a mixed picture.

Key Financial Metrics

EPS
−$0.28
est $0.21 · -233.3%
Revenue
$575.6M
est $603.7M · -4.7% · +22.1% YoY
Rating
strong miss
Guidance
$2,355-$2,405 million
raised

Key Facts

  • Total Company Revenue increased 22.1% to $575.6M in Q1 2026 from $471.4M in Q1 2025
  • GAAP Net Loss was $33.5M vs $37.9M in prior year; Net Loss Per Share was $(0.43) vs $(0.51)
  • Adjusted Diluted Loss Per Share was $(0.28), missing consensus estimate of $0.21 by 236.1%
  • Total Company Adjusted EBITDA increased 36.3% to $63.3M from $46.4M
  • Digital Health revenue grew 51.5% to $29.1M; ARR doubled to $96.9M from $49.8M
  • Revised FY2026 Imaging Center guidance: Revenue raised to $2,355-$2,405M, Adjusted EBITDA to $340-$353M, Free Cash Flow to $112-$122M
  • Aggregate advanced imaging procedural volumes increased 19.7%; same-center advanced imaging up 8.2%
  • Cash balance of $455.3M; Net Debt to Adjusted EBITDA leverage ratio slightly below 2.0x
  • Q1 results impacted by ~$13M revenue and ~$9M Adjusted EBITDA loss from severe winter weather
  • Signed over $16M in Total Contract Value of new DeepHealth business during Q1

Financial Impact

Revenue beat prior year by $104.2M (+22.1%), but GAAP net loss of $33.5M and adjusted EPS miss of $(0.28) vs $0.21 consensus (-236.1%)

revenueepsadjusted_ebitdafree_cash_flownet_income

Risk Factors

  • Adjusted EPS of $(0.28) missed consensus of $0.21 by 236%, which could trigger negative analyst revisions
  • GAAP net loss continues despite revenue growth; operating loss of $23.9M in the quarter
  • Digital Health Adjusted EBITDA declined to $1.3M from $3.7M due to infrastructure investments
  • Weather impact reduced Q1 revenue by ~$13M and Adjusted EBITDA by ~$9M, creating noise in comparisons
  • Cash balance dropped from $767M to $455M due to acquisitions and capex

Market Snapshot

Exchange
Nasdaq
Sector
Services-Medical Laboratories
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001683168-26-003624
Document: 0001683168-26-003624-index.html0001683168-26-003624
Document: 0001683168-26-003624.txt0001683168-26-003624
8-K Data (Synthetic)0001683168-26-003624

US Market Status

Market Closed · Opens Wed (12h 39m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 11, 2026